Abstract
Genetic variations in MDM2, PTEN and P53 might be involved in cancer susceptibility. To assess the contribution of polymorphisms in these three genes to the risk of esophageal squamous cell carcinoma (ESCC) in a Chinese population, we genotyped MDM2 T309G, Del1518, PTEN rs701848, rs2735343 and P53 Arg72Pro polymorphisms using PCR-restriction fragment length polymorphism analysis in 226 ESCC cases and 226 cancer-free controls. Here we showed that the risk of ESCC was elevated in subjects with any of the variant genotypes of PTEN rs2735343 and P53 Arg72Pro polymorphisms, but not any genotype of MDM2 or PTEN rs701848. Moreover, multiplicative interactions were observed between PTEN rs2735343 and P53 Arg72Pro or smoking status on risk of ESCC. Our study firstly indicated that PTEN rs2735343 might be a susceptibility factor for ESCC and reaffirmed the role of P53 Arg72Pro in ESCC in this Chinese population, but did not replicate the positive association between MDM2 T309G and ESCC found previously.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Momand, J., Zambetti, G. P., Olson, D. C., George, D. & Levine, A. J. The mdm2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell. 69, 1237–1245 (1992).
Haupt, Y., Maya, R., Kazaz, A. & Oren, M. Mdm2 promotes the rapid degradation of p53. Nature. 387, 296–299 (1997).
Yin, Y. & Shen, W. H. PTEN: a new guardian of the genome. Oncogene. 27, 5443–5453 (2008).
Lindsey, D. M., Jack, E. D., Donald, L. D., Nickolas, K. T. & David, B. D. PTEN protects p53 from Mdm2 and sensitizes cancer cells to chemotherapy. J. Biol. Chem. 277, 5484–5489 (2002).
Lindsey, D. M. & David, B. D. The PTEN, MDM2, P53 tumor suppressor oncoprotein network. Trends. Biochem. Sci. 27, 9 (2002).
Bond, G. L., Hu, W., Bond, E. E., Robins, H., Lutzker, S. G., Arva, N. C. et al. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell. 119, 591–602 (2004).
Bond, G. L., Hu, W. & Levine, A. A single nucleotide polymorphism in the MDM2 gene: from a molecular and cellular explanation to clinical effect. Cancer. Res. 65, 5481–5484 (2005).
Ohmiya, N ., Taguchi, A ., Mabuchi, N ., Itoh, A., Hirooka, Y., Niwa, Y. et al. MDM2 promoter polymorphism is associated with both an increased susceptibility to gastric carcinoma and poor prognosis. J. Clin. Oncol. 24, 4434–4440 (2006).
Dumont, P., Leu, J. I., Della, A. C., George, D. L. & Murphy, M. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat. Genet. 33, 357–365 (2003).
Chang, F., Syrjänen, S., Wang, L. & Syrjänen, K. Infectious agents in the etiology of esophageal cancer. Gastroenterology 103, 1136–1148 (1992).
Hiyama, T., Yoshihara, M., Tanaka, S. & Chayama, K. Genetic polymorphisms and esophageal cancer risk. Int. J. Cancer. 121, 1643–1658 (2007).
Xing, D., Tan, W. & Lin, D. Genetic polymorphisms and susceptibility to esophageal cancer among Chinese population (review). Oncol. Rep. 10, 1615–1623 (2003).
Lee, J.M., Lee, Y.C., Yang, S. Y., Shi, W. L., Lee, C.J., Luh, S.P. et al. Genetic polymorphisms of p53 and GSTP1, but not NAT2, are associated with susceptibility to squamous cell carcinoma of the esophagus. Int. J. Cancer. 89, 458–464 (2000).
Cai, L ., Mu, L.N., Lu, H ., Lu, Q.Y., You, Y ., Yu, S.Z. et al. Dietary selenium intake and genetic polymorphisms of the GSTP1 and p53 genes on the risk of esophageal squamous cell carcinoma. Cancer. Epidemiol. Biomarkers. Prev. 15, 294–300 (2006).
Zhang, L ., Xing, D ., He, Z . & Lin, D . P53 gene codon 72 polymorphism and susceptibility to esophageal squamous cell carcinoma in a Chinese population. Zhonghua. Yi. Xue. Yi. Chuan. Xue. Za. Zhi. 19, 10–13 (2002).
Hong, Y ., Miao, X.P., Zhang, X.M., Ding, F ., Luo, A.P., Guo, Y.L. et al. The role of P53 and MDM2 polymorphisms in the risk of esophageal squamous cell carcinoma. Cancer. Res. 65, 9582–9587 (2005).
Ge, H., Cao, Y. Y., Chen, L. Q., Wang, Y. M., Chen, Z. F., Wen, D. G. et al. PTEN polymorphisms and the risk of esophageal carcinoma and gastric cardiac carcinoma in a high incidence region of China. Dis. Esophagus. 21, 409–415 (2008).
Stephens, M., Smith, N. J. & Donnelly, P. A new statistical method for haplotype reconstruction from population data. Am. J. Hum. Genet. 68, 978–989 (2001).
Sholom, W., Debra, T. S., Joseph, K. M. & Jack, S. M. Selection of Controls in Case-Control Studies. Am. J. Epidemiol. 135, 1029–1041 (1992).
Hu, Z. B., Ma, H. X., Lu, D. R., Qian, J., Zhou, J. N., Chen, Y. J. et al. Genetic variants in the MDM2 promoter and lung cancer risk in a Chinese population. Int. J. Cancer. 118, 1275–1278 (2006).
Ma, H. X., Hu, Z. B., Zhai, X. J., Wang, S., Wang, X. C., Qin, J. W. et al. Polymorphisms in the MDM2 promoter and risk of breast cancer: a case-control analysis in a Chinese population. Cancer. Lett. 240, 261–267 (2006).
Zhang, X. M., Miao, X. P., Guo, Y. L., Tan, W., Zhou, Y. F., Sun, T. et al. Genetic polymorphisms in cell cycle regulatory genes MDM2 and TP53 are associated with susceptibility to lung cancer. Hum. Mutat. 27, 110–117 (2006).
Xiao, M., Zhang, L., Zhu, W. H., Huang, J., Jiang, H. F., Hu, S. H. et al. Genetic polymorphisms of MDM2 and TP53 genes are associated with risk of nasopharyngeal carcinoma in a Chinese population. BMC. Cancer. 10, 147 (2010).
Zhou, G. Q., Zhai, Y., Cui, Y., Zhang, X. M., Dong, X. J., Yang, H. et al. MDM2 promoter SNP309 is associated with risk of occurrence and advanced lymph node metastasis of nasopharyngeal carcinoma in Chinese population. Clin. Cancer. Res. 13, 2627–2633 (2007).
Mitsuo, T., Muneaki, S. & Naofumi, N. Expression and prognostic significance of PTEN product protein in patients with esophageal squamous cell carcinoma. Cancer. 94, 1955–1960 (2002).
Chang, D., Wang, T. Y., Li, H. C., Wei, J. C. & Song, J. X. Prognostic significance of PTEN expression in esophageal squamous cell carcinoma from Linzhou City, a high incidence area of northern China. Dis. Esophagus. 20, 491–496 (2007).
Susan, A. T., Zhao, Z. Z., Lien, L., Krina, T. Z., Nicholas, G. M., Stephen, K. et al. Variants in EMX2 and PTEN do not contribute to risk of endometriosis. Mol. Hum. Reprod. 13, 587–594 (2007).
Christopher, A. H., Daniel, O. S., Iona, C ., Elena, E.G., Loreall, P ., Kathryn, P . et al. Common genetic variation at PTEN and risk of sporadic breast and prostate cancer. Cancer. Epidemiol. Biomarkers. Prev. 15, 1021–1024 (2006).
Lynette, S. P., Cheryl, L. T., Alona, M., Sarah, J. P., Thomas, C. T., Graham, C. et al. No association between phosphatase and tensin homolog genetic polymorphisms and colon cancer. World. J. Gastroenterol. 15, 3771–3775 (2009).
Ding, J., Gao, Y. Z., Liu, R. Y., Xu, F. & Liu, H. Y. Association of PTEN polymorphisms with susceptibility to hepatocellular carcinoma in a han Chinese population. DNA. Cell. Biol. 30, 229–234 (2011).
Acknowledgements
This paper was supported by the Program of Shandong Province's Pharmaceutical Health and Technology Development (No HZ068).
Author information
Authors and Affiliations
Corresponding author
Additional information
Supplementary Information accompanies the paper on Journal of Human Genetics website
Supplementary information
Rights and permissions
About this article
Cite this article
Ma, J., Zhang, J., Ning, T. et al. Association of genetic polymorphisms in MDM2, PTEN and P53 with risk of esophageal squamous cell carcinoma. J Hum Genet 57, 261–264 (2012). https://doi.org/10.1038/jhg.2012.15
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/jhg.2012.15
Keywords
This article is cited by
-
Roles of PTEN inactivation and PD-1/PD-L1 activation in esophageal squamous cell carcinoma
Molecular Biology Reports (2022)
-
MDM2 promoter polymorphism del1518 (rs3730485) and its impact on endometrial and ovarian cancer risk
BMC Cancer (2017)
-
High-incidence of PTEN mutations in Chinese patients with primary small cell carcinoma of the esophagus
BMC Cancer (2014)
-
The regulatory roles of phosphatases in cancer
Oncogene (2014)
